FDA approves new and updated indications for temozolomide under Project Renewal

On September 14, 2023, the Food and Drug Administration (FDA) approved updated labeling for temozolomide (Temodar, Merck) under Project Renewal, an Oncology Center of Excellence (OCE) initiative aimed at updating labeling information for older oncology drugs to ensure information is clinically meani

Source: FDA Center for Drug Evaluation and Research - What's New - September 14, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news